Lilly Sees More Dealmaking as GLP-1 Wins Expand Market
Eli Lilly’s GLP-1 drugs have changed the game in obesity and diabetes. This article explains why Lilly Sees More Deal...
Choosing the best type of credit card for rewards can enhance your spending. Learn about different cards to find the one that fits your needs.
23,104 articlesEli Lilly’s GLP-1 drugs have changed the game in obesity and diabetes. This article explains why Lilly Sees More Deal...
When a CEO sells a sizable stake, investors ask: what does it mean for the stock? This piece unpacks Universal Techni...
Oil States International (OIS) faces a shifting offshore market as 2025 unfolds. This guide breaks down the likely dr...
Inside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
Three quantum hardware players—IonQ, D-Wave, and Rigetti—are confronting a tough market reality. This article breaks ...
A major settlement shines a light on insulin pen refill practices in government health programs. This article explain...
Sitting on a 1.1% S&P yield can feel underwhelming. These three dividend stocks double right now offer stronger incom...
If you’re weighing SCHD as a core holding, this guide breaks down what the Schwab U.S. Dividend Equity ETF does, what...
A high-profile health story meets everyday budgeting: how GLP-1 treatments can impact your finances, with lessons fro...
A bold forecast meets practical analysis. Explore why prediction: intuitive surgical will may become a reality by 203...
A public clash over music rights offers practical finance lessons. This article breaks down how licensing decisions i...
Policy makers and tech leaders converge to treat China as a shared risk in AI leadership, signaling potential shifts ...